Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 87189401

Next Previous
X
Search
Drug Profile

JNJ 87189401

Alternative Names: JNJ-87189401; JNJ-9401; PSMAxCD28

Latest Information Update: 24 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Nov 2023 Phase-I clinical trials in Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Hormone refractory, Second-line therapy or greater) in USA (Parenteral) (NCT06095089)
  • 27 Oct 2023 Janssen Research & Development plans a phase I trial for prostate cancer (Late-stage disease, combination therapy, Metastatic disease, Hormone refractory, second-line therapy or greater) in France and Netherlands (Parenteral) (NCT06095089).
  • 27 Oct 2023 Preclinical trials in Prostate cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top